The brighter picture came from Novartis' growth portfolio, where nearly every strategic medicine continued to post double-digit expansion. President Donald Trump's MFN pricing policy has fundamentally changed how pharmaceutical companies think about launching medicines around the world. This is the critical link between European access to medicines and U.S. pricing policy. Trading at roughly 16 times forward earnings, Novartis commands a premium valuation relative to many industry peers, leaving less room for error. It will offer investors a clearer view of whether Novartis can successfully navigate both its near-term patent cliff and the longer-term transformation of the global pharmaceutical pricing landscape.